Shares of Repligen Co. (NASDAQ:RGEN) have been given a consensus recommendation of “Buy” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $70.50.
RGEN has been the topic of a number of research reports. Zacks Investment Research lowered shares of Farmland Partners from a “hold” rating to a “sell” rating in a research report on Friday. BidaskClub lowered shares of Waterstone Financial from a “hold” rating to a “sell” rating in a research report on Friday, June 21st. Finally, ValuEngine upgraded shares of United Overseas Bank from a “sell” rating to a “hold” rating in a report on Monday, June 17th.
RGEN remained flat at $$85.00 during trading on Friday. 188,259 shares of the company’s stock were exchanged, compared to its average volume of 544,856. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84. Repligen has a 1 year low of $45.00 and a 1 year high of $87.42. The stock has a 50 day moving average of $78.38. The stock has a market cap of $4.01 billion, a PE ratio of 116.44, a P/E/G ratio of 5.17 and a beta of 1.10.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.02. The business had revenue of $60.63 million for the quarter, compared to analyst estimates of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The firm’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 earnings per share. Research analysts predict that Repligen will post 0.94 earnings per share for the current fiscal year.
In related news, Director Glenn L. Md Cooper sold 5,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the transaction, the director now directly owns 35,975 shares in the company, valued at $2,408,166.50. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Karen A. Dawes sold 1,295 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the transaction, the director now owns 118,329 shares in the company, valued at $9,152,748.15. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in RGEN. Huntington National Bank acquired a new position in shares of Repligen in the first quarter valued at $25,000. Royce & Associates LP raised its stake in shares of Repligen by 40.6% during the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 145 shares during the period. Mascoma Wealth Management LLC bought a new stake in shares of Repligen during the 1st quarter worth $41,000. Private Capital Group LLC raised its stake in shares of Repligen by 675.3% during the 1st quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 628 shares during the period. Finally, Bronfman E.L. Rothschild L.P. raised its stake in shares of Repligen by 16.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 214 shares during the period. Hedge funds and other institutional investors own 84.90% of the company’s stock.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: Analyzing a company’s cash flow statement
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.